Prevalence of CD8⁺ cytotoxic lymphocytes in human neoplasms.

ABSTRACT:

Purpose

Immune checkpoint inhibitors have recently been approved by the US FDA as first and/or second line therapy in a subset of cancer types. Recent evidence suggests that the quantity of tumor infiltrating lymphocytes (TILs) influences the likelihood of response to immune checkpoint inhibitors. Here, we set out to assess the density of CD8⁺ lymphocytes in a wide range of different cancer types and subtypes.

Methods

The density of CD8⁺ lymphocytes was compared across different cancer types using tissue microarrays (TMAs) composed of up to 50 tumor samples each from 84 different cancer types and subtypes. In total 2652 cancers and 608 normal tissues were successfully analyzed by CD8 immunohistochemistry followed by automated image analysis of digitized

SUBMITTER: Blessin NC 

PROVIDER: S-EPMC7214387 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature